Omidria (Ketorolac, Phenylephrine)

Ketorolac tromethamine, the active ingredient in Omidria, is a nonsteroidal anti‑inflammatory drug (NSAID) presented as a 0.3 mg/mL ophthalmic solution for intraocular use. It, combined with phenylephrine hydrochloride, helps maintain pupil dilation during intraocular surgery and reduces postoperative ocular pain.

GNH USA supplies Omidria as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and ophthalmic clinics worldwide.

Omidria, containing ketorolac and phenylephrine, is indicated for ophthalmic procedures involving intraocular surgery.

- Intraocular surgery: maintains pupil dilation throughout the procedure. - Post‑operative period: reduces ocular pain after surgery. - Ophthalmic inflammation: provides anti‑inflammatory effect during and after surgery.

Omidria may cause ocular and systemic reactions after administration.

Common Side Effects: - Eye irritation: mild burning or stinging on instillation. - Redness: conjunctival hyperemia. - Blurred vision: temporary visual disturbance. - Increased intra‑ocular pressure: transient rise after dosing. - Dry eye sensation. - Headache.

Serious or Rare Side Effects: - Severe allergic reaction: anaphylaxis, angioedema. - Significant rise in intra‑ocular pressure leading to optic nerve damage. - Corneal edema or ulceration. - Endophthalmitis (intra‑ocular infection). - Systemic hypertension or tachycardia. - Vision loss.

Before using Omidria, clinicians should consider patient‑specific factors and monitor for adverse events.

- Assess ocular history: avoid in patients with narrow‑angle glaucoma. - Monitor intra‑ocular pressure: phenylephrine may increase pressure. - Check for hypersensitivity: do not use if known allergy to NSAIDs or phenylephrine. - Use with caution in cardiovascular disease: phenylephrine can raise systemic blood pressure. - Pregnancy and lactation: safety not established; use only if benefits outweigh risks. - Store at room temperature: keep in the original container, protect from light and moisture.

Omidria can interact with systemic and ocular agents; appropriate monitoring is advised.

Major Interactions (Avoid): - Systemic NSAIDs: increased risk of bleeding. - MAO inhibitors: may potentiate hypertensive response to phenylephrine. - Other sympathomimetic agents: additive vasoconstriction.

Moderate Interactions (Monitor Closely):\n- Beta‑blockers: may blunt systemic cardiovascular effects. - Antihypertensives: monitor blood pressure for additive effects. - Other ocular mydriatics: cumulative pupil dilation may be excessive.